There exists a good opportunity to achieve savings in Ohio's Medicaid drug program without cutting benefits or quality of care.

US/EU companies that protect their drug brands in turn protect our lives. We need other countries to do more and we need to help them in doing so.

The only way to improve the availability of these products is to make it possible for firms to keep pace with rising production costs and earn enough returns to invest back in better manufacturing that enables stable, safe, and more scalable supply.

Technological developments have driven the obesity plague, but technological change may also be more successful at reducing obesity than attempts to change people's eating and exercising habits have been.

The search for better anti-addiction medications is worthy, but we have to be realistic. The passive model of drug treatment for addiction is a pipe dream.

Today, nearly 80 percent of active pharmaceutical ingredients originate outside the United States. But the FDA cannot adequately oversee the safety of chemicals manufactured overseas and imported into the United States.

Requirements to test new drugs against older medicines would add a major hurdle to the development and approval of new medicines. Equally important, the proposed mandates are unnecessary.

The most sweeping reforms since 1997 are planned this year for theFDAin order to address the concern that it is not protecting the public from drugs' risks as effectively as it might.